Bluu Biosciences closes seed funding round at EUR7m
Berlin-based biotech Bluu Biosciences has closed its seed funding round at 7 million euros less than 10 months after its foundation.
Bluu Biosciences is the first company in Europe to specialise in the development and production of cell-based fish. There is currently only a handful of other companies active in this field worldwide. Global food and impact investors such as Manta Ray Ventures (UK), CPT Capital (UK), Lever VC (USA), Norrsken (SE) and Be8 (GER) participated in the investment round. The fresh capital will flow into the company's intensive biotechnology research and development work as well as into product development. The founding of Bluu Biosciences was supported by the Berlin-based company builder EVIG, which specialises in working with scientists to build biotechnology start-ups in the food sector.
“We are proud that we could partner with investors such as Manta Ray, CPT, Lever, and more, that believe in the importance of deep innovation for the aim of a more sustainable food system,” explains Dr Sebastian Rakers, Co-Founder and Managing Director of Bluu Biosciences. “The round was closed in a matter of weeks, which indicates how compelling the science team and the science foundation of Bluu is. It also showcases the incredible interest of great investors to support this kind of initiative,” adds Simon Fabich, Co-Founder and Managing Director.